Eli Lilly becomes first drugmaker to hit $1 trillion market value on weight-loss drug boom

Eli Lilly reached a $1 trillion market valuation, driven by the success of its obesity treatments, Mounjaro and Zepbound. Lilly's stock surged over 35% this year, with its obesity and diabetes portfolio generating over $10.09 billion in the latest quarter. Analysts project the weight-loss drug market could reach $150 billion by 2030, with Lilly and Novo Nordisk leading global sales.